Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00861627
Other study ID # REO 016
Secondary ID
Status Completed
Phase Phase 2
First received March 12, 2009
Last updated December 1, 2015
Start date March 2009
Est. completion date November 2015

Study information

Verified date December 2015
Source Oncolytics Biotech
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this Phase 2 study is to investigate whether intravenous administration of a wild type reovirus (REOLYSIN®) in combination with paclitaxel and carboplatin is effective and safe in the treatment of Non-Small Cell Lung Cancer with KRAS or EGFR activation.


Description:

Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) is a naturally occurring, ubiquitous, non-enveloped human reovirus. Reovirus has been shown to replicate selectively in Ras-transformed cells causing cell lysis. Activating mutations in ras or mutation in oncogenes signaling through the ras pathway may occur in as many as 80% of human tumors. The specificity of the reovirus for Ras-transformed cells, coupled with its relatively nonpathogenic nature in humans, makes it an attractive anti-cancer therapy candidate.

Given the ability of reovirus to replicate and cause oncolysis in Ras-activated cells, the high incidence of K-ras mutations in lung cancers, and the Ras-mediated activation often encountered in EGFR-addicted tumors, the administration of REOLYSIN® in combination with chemotherapy is expected to result in enhanced clinical benefit in non-small cell lung cancer (NSCLC) patients with K-ras mutations and/or EGFR aberrant activation in their tumors. Patients with de novo or acquired EGFR mutations in their tumors that confer resistance to EGFR TKIs (e.g. T790) are expected to benefit as well. This is a single arm, open-label, Phase 2 study of REOLYSIN® given intravenously with paclitaxel and carboplatin every 3 weeks (21 days is defined as a cycle) in NSCLC patients with tumors driven by these pathways.

Paclitaxel at a dose of 175 mg/m2 will be given i.v. as a 3 hour infusion on Day 1 followed by carboplatin given i.v. AUC 5 mg/mL•minute. REOLYSIN® will be given over 60 min on Day 1 (starting after completion of the carboplatin infusion), and on Days 2 - 5. The treatment cycle will be repeated every 21 days.

Patients will receive 4 to 6 cycles of paclitaxel and carboplatin, at the treating physician's discretion according to standard of practice, in conjunction with REOLYSIN®. After completion of the 4 to 6 cycles of paclitaxel and carboplatin, REOLYSIN® may be continued as monotherapy Days 1-5 of each 21 day cycle until there is evidence of disease progression or unacceptable toxicity. Patients may continue to receive therapy under this protocol, provided they have not experienced either progressive disease or unacceptable drug-related toxicity that does not respond to either supportive care or dose reduction.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date November 2015
Est. primary completion date September 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- have histologically or cytologically confirmed stage IIIB (pleural effusion; IVA on revised IASLC staging) or stage IV, or recurrent, non-small cell lung cancer with evidence of RAS- or EGFR- activation in their tumors, as defined by EGFR activating mutations in exons 18 to 21, EGFR FISH amplification, or K-ras mutations in exon 2 (codons 12,13,61).

- have evidence of measurable disease. For patients previously irradiated, the measurable lesion(s) must be outside of the treated field.

- be chemotherapy naïve for their metastatic or recurrent NSCLC. Prior adjuvant chemotherapy or chemo-XRT for treatment of localized disease is allowed, provided it has been = 6 months since the last chemotherapy infusion. Previous radiation for palliative purposes is also allowed, as long as it has been =4 weeks from the last dose.

- Patients who have been previously treated with EGFR tyrosine kinase inhibitors as their only systemic treatment are eligible, provided this treatment has been discontinued for =4 weeks. Patients who have received erlotinib as first line treatment without chemotherapy and experience tumor progression will be eligible.

- have NO continuing acute toxic effects (except alopecia) of any prior radiotherapy, chemotherapy, or surgical procedures, i.e., all such effects must have resolved to Common Terminology Criteria for Adverse Events (CTCAE, version 3.0) Grade = 1. Surgery (except biopsies) must have occurred at least 28 days prior to study enrollment.

- have an ECOG Performance Score of = 2.

- have a life expectancy of at least 3 months.

- have baseline laboratory results as follows:

- Absolute neutrophil count (ANC) = 1.5 x 10E9 [SI units 10^9/L]

- Platelets = 100 x10E9 [SI units 10E9/L] (without platelet transfusion)

- Hemoglobin = 9.0 g/dL [SI units gm/L] (with or without RBC transfusion)

- Serum creatinine = 1.5 x upper limit of normal (ULN)

- Bilirubin = 1.5 x ULN

- AST/ALT = 2.5 x ULN

- Negative pregnancy test for females of childbearing potential.

- be willing and able to comply with scheduled visits, the treatment plan, and laboratory tests.

Exclusion Criteria:

- Receive concurrent therapy with any other anticancer agent while on study.

- Received chemotherapy within 6 months, or radiotherapy or EGFR therapy within 4 weeks, prior to entering the study or have not recovered from adverse events due to agents administered more than 4 weeks earlier.

- Have brain metastases. Patients with resected oligometastasis are eligible if post resection MRI demonstrates resolution. Gamma knife treated patients are also eligible, if there are no more than two treated metastases confined to the same area of the brain and a post treatment MRI shows a decrease in the metastases.

- Have = grade 2 peripheral neuropathy at baseline.

- Have uncontrolled cardiac dysfunction, including a myocardial infarction in the preceding 6 months, or known cardiac ejection fraction < 40%.

- Be on immunosuppressive therapy or have known HIV infection or active hepatitis B or C.

- Be a pregnant or breast-feeding woman. Female patients of childbearing potential must agree to use effective contraception, must be surgically sterile, or must be postmenopausal. Male patients must agree to use effective contraception or be surgically sterile. Barrier methods are a recommended form of contraception.

- Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/ social situations that would limit compliance with study requirements.

- Have dementia or altered mental status that would prohibit informed consent.

- Have any other severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Principal Investigator, would make the patient inappropriate for this study.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Biological:
REOLYSIN®
3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
Drug:
Carboplatin
5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
Paclitaxel
175 mg/m2, 3 hour intravenous infusion, given on Day 1 of 21 day cycle

Locations

Country Name City State
United States The Ohio State University Medical Center, James Cancer Hospital and Solove Research Institute Columbus Ohio
United States Georgetown University Medical Center Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Oncolytics Biotech

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the objective response rate (complete response (CR) + partial response (PR)) of the treatment regimen in the study population For PR or CR, changes in tumor measurements must be confirmed 4 weeks after the criteria for response are first met. No
Secondary Determine the median duration of progression-free survival of patients receiving the study treatment. during and following study No
Secondary Determine the median to 1-year survival of patients receiving the study treatment. up to one year No
Secondary Evaluate the safety and tolerability of REOLYSIN® in combination with paclitaxel and carboplatin in this patient population. within 30 days of last dose of REOLYSIN® Yes
Secondary Determine the proportion of patients receiving the above treatment who are alive and free of disease progression at 6 months 6 months No
See also
  Status Clinical Trial Phase
Recruiting NCT04486833 - Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib Phase 1/Phase 2
Terminated NCT00321308 - Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer Phase 2
Completed NCT00190840 - A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer Phase 2
Terminated NCT01441128 - -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer Phase 1
Recruiting NCT05358249 - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Phase 1/Phase 2
Terminated NCT02961283 - Study of ASN003 in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT00973310 - Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer Phase 2
Completed NCT00385996 - Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer Phase 2
Terminated NCT02775006 - Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma Phase 3
Completed NCT03232593 - A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Terminated NCT02590003 - Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer Phase 2
Terminated NCT01514864 - Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation Phase 2
Completed NCT00070629 - CPG 7909 Injection in Non-Small Cell Lung Cancer Phase 2
Completed NCT02079636 - A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Phase 1
Terminated NCT01115803 - A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors Phase 1
Completed NCT01079520 - Endobronchial Ultrasound- Transbronchial Needle Aspiration (EBUS-TBNA) Versus Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer (NSCLC) N/A
Completed NCT00923884 - Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
Recruiting NCT04389632 - A Study of SGN-B6A in Advanced Solid Tumors Phase 1
Terminated NCT03603652 - NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung N/A
Not yet recruiting NCT01131429 - A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations Phase 2